OpenEye Scientific and Specifica Partner to Launch Orion® Antibody Discovery Suite incorporating AbXtract™
- Wall Street rallies as Fed minutes meet expectations
- NVIDIA Shares Drop 6% on Disappointing Guidance, While Q1 Earnings Beat
- Apple (AAPL) Reportedly Behind Schedule in Development of the New iPhone, Analyst Cuts Price Target on Risk to June Quarter iPhone Revenue
- Oil edges higher on tight supply, rising U.S. refining activity
- After-Hours Stock Movers 05/25: NVIDIA, Snowflake Sink on Weaker Guidance; Williams-Sonoma Surges on Strong Numbers (more...)
Next Generation Sequencing Software to Help Antibody Engineers, Bioinformaticians Uncover Potential Antibody Therapeutics
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
SANTA FE, N.M., Dec. 2, 2021 /PRNewswire/ -- OpenEye Scientific and Specifica, Inc., today announced they are releasing jointly developed software to help antibody engineers and bioinformaticians at pharmaceutical and biotechnology companies advance antibody discovery by identifying diverse antibody sets with better properties for downstream therapeutics development.
Now available for launch customers, OpenEye's Orion® Antibody Discovery Suite exclusively includes AbXtract™, an antibody discovery module developed by Specifica that is the first offering in the suite. AbXtract uses proprietary artificial intelligence methods to help antibody engineers and bioinformaticians analyze vast amounts of sequence data to uncover potential antibody therapeutics.
Orion, the only cloud-native fully integrated software-as-a-service molecular modeling platform, accelerates drug discovery science by combining the unlimited storage and computational scalability of Amazon Web Services with powerful tools for data sharing, visualization and analysis in an open development platform.
"We are excited to partner with OpenEye Scientific, a company that shares our vision of enabling teams of any size to undertake large-scale antibody discovery efforts," said Andrew Bradbury, Co-Founder and Chief Scientific Officer of Specifica. "We use next generation sequencing extensively at Specifica, and initially developed various bioinformatics tools for our in-house research. We then realized that many other antibody engineers could benefit and that led to the development of AbXtract.
"Using AbXtract for antibody discovery can be as simple as uploading a file to Orion and indicating how many leads are desired," Bradbury said. "Expert users also can adjust many different parameters. What AbXtract does is democratize the use of next generation sequencing in antibody discovery, letting Orion take care of storage and analysis. Antibody discovery projects that were previously out of reach because of software, hardware, computation, or data sharing limitations have now become possible with AbXtract on Orion."
Orion features an easy-to-use, web-based graphical interface and sophisticated analysis and reporting workflows. With the AbXtract antibody discovery module in the Orion Antibody Discovery Suite, researchers can process and characterize tens of millions of sequences, extract sequence- and function-based features, identify promising antibody leads, as well as share data and collaborate – all in real time.
"For nearly 25 years, world-leading organizations have relied on OpenEye to speed up their small molecule design efforts in drug discovery," said Anthony Nicholls, CEO of OpenEye Scientific. "With our ground-breaking Orion platform, we can bring new science from exciting companies like Specifica to those customers seamlessly and efficiently. As therapeutic antibody discovery becomes increasingly important for treating disease, it is a privilege to partner with Specifica."
About SpecificaSpecifica's mission is to empower companies that create cures with visionary antibody technologies. Specifica's Generation 3 Antibody Library Discovery Platform yields drug-like antibodies, with broad diversity, high affinities, and few biophysical liabilities directly from selections, minimizing the need for affinity and biophysical engineering. In addition to in-house antibody library designs, Specifica also collaborates closely with partners to create custom libraries in which essential elements are optimized according to partner needs. Specifica is headquartered in Santa Fe, New Mexico. For more information, please visit www.specifica.bio and follow Specifica on Twitter and LinkedIn.
About OpenEye ScientificOpenEye Scientific is an industry leader in computational molecular design through rapid, robust, and scalable software, toolkits, technology and design services, and Orion®, the only cloud-native fully integrated software-as-a-service molecular modeling platform. Combining unlimited computation and storage with powerful tools for data sharing, visualization and analysis in an open development platform, Orion offers unprecedented capabilities for the advancement of pharmaceuticals, biologics, agrochemicals, and flavors and fragrances. Founded in 1997, OpenEye is a privately held company headquartered in Santa Fe, N.M., with offices in Boston, Mass.; Cologne, Germany; and Tokyo, Japan. For more information, go to www.openeye.inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/openeye-scientific-and-specifica-partner-to-launch-orion-antibody-discovery-suite-incorporating-abxtract-301436373.html
SOURCE OpenEye Scientific
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IFS Named A Leader in IDC MarketScape for Worldwide SaaS and Cloud-Enabled Manufacturing ERP in 2022
- DXC Technology, Lloyd's and IUA Extend Contract to Support Transformation of London Insurance Market
- Rebeccatech Closes Series A+ on MicroRF Technology
Create E-mail Alert Related CategoriesPRNewswire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!